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Abstract: Antiangiogenesis options have evolved rapidly in the last few years, with an 
increasing number of agents currently approved by the US Food and Drug Administration and 
European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for 
the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular 
endothelial growth factor receptor and is currently being developed for the treatment of various 
malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, 
with minimal adverse reactions and enhanced safety. In a large Phase III study of previously 
treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free 
survival than sorafenib with an acceptable safety profile and good quality of life. This review 
focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current 
treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting 
needs to be evaluated in further clinical trials.
Keywords: axitinib, renal cell carcinoma, vascular endothelial growth factor receptor, 
angiogenesis
Introduction
Renal cell carcinoma (RCC) accounts for almost 85% of all kidney cancers.1 Over 
120,000 cases of RCC are currently diagnosed each year in Europe and the USA,2,3 and 
the incidence of RCC appears to be rising.4,5 Approximately 30% of patients present with 
metastatic disease and 25% with locally advanced RCC.4 RCC one of the malignancies 
most resistant to conventional cytotoxic chemotherapy.6 Moreover, up to 40%–50% of 
patients who undergo curative renal resection go on to develop metastatic or advanced 
RCC.7,8 The 5-year survival rates for patients with kidney cancer, according to the 
American Joint Committee on Cancer staging classification, are 81% for stage I, 74% 
for stage II, 53% for stage III, and 8% for stage IV.4 According to the Surveillance, 
Epidemiology, and End Results Program database, the 5-year survival rates are 91.7% 
for localized, 64.2% for regional, 12.3% for distant, and 33.5% for unstaged disease.9
Before 2005, standard of care was limited to cytokine therapy with interleukin-2 
and/or interferon-alpha (IFN-α). These treatments were associated with limited effi-
cacy and high toxicity, and remained an option for first-line treatment in only a small 
minority of highly selected patients with a good prognosis.10–12
More recently, a better understanding of the molecular mechanisms involved in 
the pathogenesis of RCC led to treatment options that target angiogenesis by direct 
inhibition of vascular endothelial growth factor (VEGF)-mediated signaling and by 
inhibition of the mammalian target of rapamycin (mTOR) that targets downstream 
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signaling and tumor metabolism as well.13–15 Several of these 
novel targeted regimens (bevacizumab, IFN-α combination, 
sorafenib, temsirolimus, sunitinib, pazopanib, everolimus, 
and axitinib) have subsequently been evaluated in large 
robust randomized controlled trials conducted in both the 
first-line and second-line settings.16 Data from these clinical 
trials have showed superior progression-free survival with 
targeted agents compared with IFN-α and placebo (in the 
second-line setting).17 As a result of the efficacy results and 
the US and European regulatory approval for several of 
these agents, many organizations have updated their clinical 
practice guidelines.18,19 Despite the proliferation of targeted 
agents approved by the US Food and Drug Administration, 
RCC continues to have a deleterious impact. In 2012, RCC 
was the seventh most common malignancy in the US, with an 
estimated new 65,150 cases and 13,680 deaths in 2013.5
Multiple novel therapies targeting the mTOR and VEGF 
signaling pathways have been introduced into clinical prac-
tice, resulting in significant improvements in outcomes for 
patients with metastatic RCC, compared with cytokine-based 
therapy, ie, the previous standard of care. Therapies currently 
approved in the USA and European Union for treatment of 
patients with metastatic RCC targeting the VEGF pathway 
include bevacizumab (plus IFN-α), a humanized monoclonal 
antibody that inhibits binding of VEGF to its receptor, and 
the multitargeted receptor tyrosine kinase inhibitors (TKIs) 
sunitinib, sorafenib, and pazopanib.20–24 These agents have 
diverse molecular profiles and different affinities for VEGF 
and platelet-derived growth factor receptors, inhibiting some 
but not all proangiogenic receptors.25 The mTOR inhibitors 
currently approved for treating patients with metastatic RCC 
are everolimus and temsirolimus.26,27
Axitinib (Inlyta®; Pfizer Inc., New York, NY, USA) is a 
third-generation VEGF receptor inhibitor that is highly selec-
tive and potent for VEGF receptors 1, 2, and 3 at clinically 
achievable doses compared with many other antiangiogenic 
agents in its class. Based on its efficacy in terms of progres-
sion-free survival compared with sorafenib in the second-line 
setting (AXIS [axitinib versus sorafenib in advanced renal 
cell carcinoma] trial),28 in 2012 both the US Food and Drug 
Administration29 and the European Medicines Agency (report 
EMA/CHMP/453325/2012) approved axitinib for use in the 
second-line treatment of patients with metastatic RCC after 
failure of prior treatment with sunitinib or a cytokine.
Pharmacology/mode of action
Axitinib (AG-013736) is a substituted indazole 
 chemically known as N-methyl-2-[3-(E)-2-pyridin-2-
yl-vinyl-1H-indazol-6-ylsulfanyl] benzamide, having 
the formula C
22
H
18
N
4
OS and a molecular weight of 
386.47 Da (Figure 1). Its synthesis is described under US 
Patent 6,534,524.30 Axitinib is a third-generation, small-
molecule, competitive inhibitor binding to the ATP-binding 
domain of VEGF receptor 1, 2, and 3 TKIs. Inhibition 
occurs at nanomolar concentrations and is equally selec-
tive for VEGF receptors 1, 2, and 3 compared with other 
tyrosine kinase receptors, such as c-KIT and platelet-derived 
growth factor receptor-β (Table 1).31 In endothelial cells, 
inhibition of VEGF receptors 1 and 2 by axitinib produces 
a rapid and dose-dependent reduction in phosphorylation 
of Akt, endothelial nitric oxide synthase, and extracellular 
signal-related kinase 1/2. In several in vivo mouse tumor 
models, axitinib showed antitumor efficacy in association 
with decreased vascular angiogenesis and increased tumor 
apoptosis.32
Pharmacokinetics
A Phase I study showed that axitinib is rapidly absorbed 
when administered with food, with peak plasma concentra-
tions occurring at 2–6 hours following dosing. When dosed 
in a fed state, peak plasma concentration and area under the 
plasma concentration-time curve over 24 hours (AUC
0–24h
) 
are decreased compared with the fasted state (coefficient 
of variation 90% and 63%, respectively). Peak concentra-
tions occur 1–2 hours after dosing in the fasted state. Food 
affects the bioavailability of axitinib; plasma exposure 
increases by a median of 49% when axitinib is dosed in 
the fasted state. Pharmacokinetic assessment suggests a 
linear dose-proportional relationship between peak plasma 
concentration and AUC
0–24h
 (Figure 2).33 The terminal 
H
O
S N
N
N
N
H3C
H
Figure 1 Chemical structure of axitinib.
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half-life of axitinib is 6–7 hours.34 In the Phase I study, it 
was discovered that the aqueous solubility of AG-013736 is 
pH-dependent, with low pH conferring the highest solubility. 
However, drug concentrations were not significantly affected 
by the proton pump inhibitor rabeprazole.33 Other contribu-
tions to absorption of axitinib are the ATP-binding cassette 
(ABC) transporters P-glycoprotein (ABCB1/MDR-1) and 
breast cancer resistance protein (BCRP/ABCG2).35 These 
transporters are expressed on the apical membranes of 
enterocytes, hepatocytes, renal tubular epithelial cells, and 
brain endothelial capillary cells of the blood–brain barrier, 
affecting the extent of absorption, secretion, and distribution 
of certain anticancer drugs across the blood–brain barrier. 
Transport assay studies and pharmacokinetic studies in 
knockout mice have demonstrated a major role of ABCB1 
in limiting accumulation of axitinib in the brain, compared 
with ABCG2 that in turn has an impact on oral bioavailability 
and plasma axitinib concentrations.35 Based on the studies in 
mice, there is a concern about an increased risk of adverse 
drug reactions in humans when ABCG2-inhibiting drugs, 
such as pantoprazole, are coadministered with axitinib, 
resulting in decreased hepatobiliary excretion or increased 
gastrointestinal absorption.35
The effects of ABCB1 and ABCB2 transporters on drug 
concentrations in brain and plasma are not only important 
for clinical efficacy but may also be relevant to drug resis-
tance, because ABCB1 (MDR-1) expression correlates with 
a poorer prognosis in RCC patients.36 Further investigation 
will be needed to elucidate this point fully.
Cytochrome P450 (CYP) subfamily member CYP3A4 
accounts for the majority of hepatic metabolism of axitinib, 
with a smaller proportion being metabolized by CYP1A2, 
CYP2C19, and glucuronidation.37 Two nonactive metabo-
lites are formed, ie, the M7 sulfoxide metabolite, which is a 
byproduct of the CYP system, and the M12 N-glucuronide 
metabolite, via the glucuronidation pathway. Ketoconazole, 
a CYP3A4 inhibitor, significantly increased the peak plasma 
concentration (by ∼1.5-fold) and AUC
0–24h
 (by ∼2-fold).37
In a Phase I study, rifampin, a potent inducer of the 
CYP system, decreased the peak plasma concentration and 
AUC
inf
 of axitinib by 71% and 79%, respectively. Similarly, 
phenytoin, another potent inducer of multiple CYP enzymes, 
reduced the AUC
0–24h
 and peak plasma concentration of 
AG-013736 by approximately 10-fold, as observed in a 
single patient.33 Glucuronidation of axitinib occurs via uridine 
diphosphate glucuronosyl-transferase (UGT)1A1. Patients 
homozygous for the UGT1A1*28 variant gene may have 
increased exposure to drugs metabolized through this path-
way, as exemplified by irinotecan.38 The pharmacokinetics of 
axitinib were assessed in four subjects (three Caucasian and 
one Japanese) known to have the variant UGT1A1*28 allele. 
In this small population, pharmacokinetic parameters were 
similar to those lacking the variant, suggesting that patients 
with the UGT1A1*28 polymorphism probably do not require 
modification of their axitinib dose.34 A comprehensive list 
of CYP3A4 inducers is reported in Table 2.
The fundamental Phase I dose-escalation study in patients 
with advanced solid tumors dosed patients from 5 mg twice 
daily to 30 mg twice daily. This study also explored the effects 
of food on the bioavailability of axitinib, as described earlier. 
Dose-limiting toxicities were realized at doses of 10 mg 
twice daily and higher. Two patients with non-small cell 
adenocarcinoma of the lung initially received 20 mg twice 
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Figure 2 Mean steady-state plasma concentrations on day 15 of dosing (maximum 
concentration versus dose). 
Note: Patson B, Cohen RB, Olszanski AJ, Expert Opinion on Drug Metabolism & 
Toxicology, 8(2):259–270.30 Copyright © 2012, informa Healthcare. Reproduced with 
permission of informa Healthcare.
Abbreviations: bid, twice daily; qd, once daily; Cmax, maximum concentration.
Table 1 iC50 values determined by receptor phosphorylation 
assays
Target kinase IC50 (nmol/L) Assayed cells
veGFR-1 0.06 HUveC
veGFR-2 0.1 HUveC
veGFR-3 0.1–0.3 PAe
PDGFR-β 2.9 NiH-3T3
Notes: iC50 values were measured by immunoprecipitation/immunoblotting in the 
presence of 1% fetal bovine serum (HUveC) or 0.1% fetal bovine serum (PAe or 
NiH3T3). The data were corrected for protein binding with the consideration that 
the presence of 2.3% bovine serum albumin typically shifted cellular iC50 values up by 
a factor of ten. Reprinted from Clinical Cancer Research, 2008, 14(22), 7272–7283,32 
Hu-Lowe D, Zou H, Grazzini M, et al, Nonclinical antiangiogenesis and antitumor 
activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular 
endothelial growth factor receptor tyrosine kinases 1, 2, 3, with permission from 
AACR. Copyright © 2008, American Association for Cancer Research. 
Abbreviations: PAe, porcine aortic endothelial; PDGFR-β, platelet-derived 
growth factor receptor-beta; veGFR, vascular endothelial growth factor receptor; 
HUveC, human umbilical vein endothelial cells.
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daily (subsequently reduced to 10 mg twice daily) and died 
of fatal hemoptysis, which was considered to be treatment-
related in one case. Additionally, two patients had hyperten-
sive seizures at respective doses of 20 mg and 10 mg twice 
daily.33 Therefore, the dose of 5 mg twice daily in the fasted 
state given continuously for a 28-day cycle was selected for 
subsequent clinical development of axitinib.33 Further investi-
gation of axitinib led to the discovery of various crystal forms. 
Axitinib developed as the polymorph form XLI had a similar 
pharmacokinetic profile in the fed and fasted state in healthy 
human volunteers.41 The primary toxicity, and a class effect 
seen across similar VEGF receptor-targeted compounds, 
was hypertension (all grades), which developed in 61% of 
patients. At doses of 5 mg twice daily, hypertension was 
manageable using standard antihypertensive agents. Other 
primary toxicities included fatigue, diarrhea, stomatitis, 
nausea, and vomiting.
Early Phase I and II studies
The principal evidence for the clinical efficacy of axitinib 
in subjects with advanced/metastatic RCC is derived from 
two studies: a Phase II single-arm trial in cytokine-refractory 
patients; and a multicenter, randomized Phase III study of 
axitinib as a second-line therapy in patients with metastatic 
RCC. The single-arm, open-label, multicenter Phase II study 
of axitinib in subjects with advanced RCC after failure of 
treatment with one prior cytokine-based therapy42 enrolled 
52 subjects. Efficacy endpoints included overall response 
rate (primary endpoint), progression-free survival, time to 
tumor progression, duration of response, and overall survival. 
Patients with progressive metastatic RCC were given a start-
ing dose of axitinib 5 mg twice daily in the fasted state. Treat-
ment was continued until no longer of clinical benefit. The 
patients had a median age of 59 years and were mainly males 
(77%). The majority had a previous nephrectomy (94%), and 
almost all had tumors with clear-cell histology (98%; one 
patient had papillary histology). All patients had received 
prior treatment with cytokines, the most common of which 
was IFN alone (52%). Overall, 58% of patients had at least 
one Memorial Sloan Kettering Cancer Center risk factor (ie, 
at least one poor prognostic factor) for second-line treatment. 
The investigator-assessed overall response rate was 44.2% 
(95% confidence interval [CI] 30.5–58.7), with two patients 
achieving a complete response and 21 patients achieving a 
partial response. Stable disease for 8 weeks or longer was 
reported in 22 patients (42%), with 13 patients (25%) achiev-
ing stable disease for 24 weeks or longer. Median response 
duration was 23.0 months (95% CI 20.9, not estimable). 
Maximum percentage decrease in target lesion size, based 
on Response Evaluation Criteria In Solid Tumors (RECIST) 
is shown in Figure 3. A decrease of more than 30% indicates 
a potential partial response, while a 100% decrease indicates 
a potential complete response. The vast majority of patients 
had some degree of tumor shrinkage (81%; 42/52). Only two 
of the five patients with a 100% decrease in target lesion size 
were judged to have a complete response. Median overall 
survival was 29.9 months (95% CI 20.3, not estimable) with a 
median follow-up of 31 months. Median time to progression 
was 15.7 months (95% CI 8.4–23.4) and one-year survival 
was 78.8% (95% CI 67.7–89.9).
In the other single-arm, open-label, multicenter Phase II 
study of axitinib in subjects with advanced RCC after failure 
of treatment with at least one prior sorafenib-based therapy, 
most subjects had additionally received prior treatment 
with sunitinib and/or other agents.43 Sixty-two subjects 
were enrolled and treated. Efficacy endpoints included 
overall response rate (primary endpoint), progression-free 
survival, duration of response, and overall survival. Disease 
response and progression were determined by investigators’ 
assessments. Patients had metastatic RCC refractory to prior 
therapies that included but were not limited to sorafenib. 
Axitinib was administered at a starting dose of 5 mg twice 
daily. Individual dose titrations .5 mg twice daily and 
modifications ,5 mg twice daily were permitted, based on 
individual patient tolerability. At baseline, patients had a 
median age of 60 (range 35–77) years and 66% had an 
Eastern Cooperative Oncology Group performance  status 
Table 2 Main CYP 3A4 inducers
Inducer Reference
Carbamazepine Yap et al,39 2008; 
Kiran,40 2011
Corticosteroids Kiran,40 2011
efavirenz Kiran,40 2011
Felbamate Yap et al,39 2008
Modafinil Kiran,40 2011
Nevirapine Kiran,40 2011
Omeprazole Kiran,40 2011
Oxcarbazepine Yap et al,39 2008; 
Kiran,40 2011
Phenobarbital Yap et al,39 2008
Phenytoin/phosphophenytoin Yap et al,39 2008; 
Kiran,40 2011
Primidone Yap et al,39 2008; 
Kiran,40 2011
Rifabutin Kiran,40 2011
Rifampin Kiran,40 2011
St John’s wort (Hypericum perforatum) Kiran,40 2011
Topiramate Yap et al,39 2008
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of 1. Patients in this study were heavily pretreated; in fact, 
all patients had prior systemic therapy with sorafenib 
and 22.6% had also received prior therapy with sunitinib. 
Approximately two thirds (61%) of patients had previously 
received cytokine therapy. The overall response rate was 
22.6%, with 14 patients achieving a partial response. Eleven 
patients (17.7%) had stable disease. The clinical benefit 
rate (complete and partial responses plus stable disease) 
was 40%. The maximal percentage reduction in target 
lesions (according to RECIST criteria) during treatment 
with axitinib was based on dose titration. Some degree of 
tumor shrinkage with axitinib was seen in 40 of 50 patients 
(80%) for whom post-baseline data were available. Twelve 
patients without a post-baseline scan were excluded due to 
study withdrawal (discontinued due to adverse events or 
withdrawal of consent); these 12 patients were on a starting 
axitinib dose of 5 mg twice daily. Tumor responses were 
observed within the group of patients who were dose-titrated 
to .5 mg twice daily (7/33; 21%), as well as in patients who 
remained on 5 mg twice daily or who were dose-modified 
to ,5 mg twice daily (7/29; 24%). Median progression-free 
survival was 7.4 months (95% CI 6.7–11.0) for all patients, 
with a median follow-up of 22.7 months.
Median progression-free survival was 9.1 months (95% CI 
7.1–11.2) in patients who received axitinib .10 mg/day and 
6.7 months (95% CI 3.7–7.6) in those who received 
#10 mg/day.
These findings suggest that total cross-resistance does not 
occur between axitinib and sunitinib, sorafenib, and cytokines 
and that axitinib may have antitumor activity in patients with 
progressive metastatic RCC.
Phase III efficacy studies
Following the results of the Phase II studies, the AXIS trial 
was designed. The Second-Line Axitinib Versus Sorafenib 
(AXIS) trial is a randomized, open-label Phase III study that 
evaluated the safety and efficacy of axitinib in patients with 
progressive metastatic clear-cell RCC who had received one 
previous line of systemic therapy, including sunitinib, beva-
cizumab + IFN-α, temsirolimus, or cytokine(s), compared 
with sorafenib. The primary endpoint was progression-free 
survival as assessed by an independent review committee 
and defined as time from randomization to either first docu-
mentation of RECIST-defined disease progression or death 
due to any cause; secondary endpoints were overall survival, 
objective (overall) response rate, and duration of response. 
The study was designed to detect a $40% improvement 
in median progression-free survival from 5 months with 
sorafenib, based on available data at that time, to 7 months 
with axitinib with a power of 90%. The patients were ran-
domized to receive axitinib 5 mg twice daily or sorafenib 
400mg twice daily. For those patients without hypertension 
or adverse reactions above grade 2, an increase in axitinib to 
7 mg and then 10 mg twice daily was allowed.
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Figure 3 Maximum percentage tumor decrease of target lesions by Response evaluation Criteria in Solid Tumors.
Notes: Bars represent individual patients. Zero represents baseline (no change); -100% represents potential complete response; greater than -30% represents potential partial 
response. excludes four patients who progressed without post-baseline scans. Reprinted from The Lancet Oncology, vol 8, Rixe O, Bukowski RM, Michaelson MD, et al, Axitinib 
treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase ii study, Pages 975–984,42 Copyright © 2014, with permission from elsevier. 
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Of 723 subjects randomized, most subjects had received 
prior sunitinib-based therapy (54%) or cytokine-based 
(interleukin-2 or IFN-α) therapy (35%); the remaining 
subjects (11%) had received one prior bevacizumab-based 
or temsirolimus-based therapy.28 Patients were assessed for 
safety at baseline and every 4 weeks thereafter by means 
of medical history and physical examination, vital signs, 
clinical laboratory evaluation, and Eastern Cooperative 
Oncology Group performance status. Safety was assessed 
throughout the study. Tumor assessments were conducted at 
screening at weeks 6 and 12, and every 8 weeks  thereafter. 
Patient-reported quality of life was measured using two 
quality of life instruments, ie, The Functional Assessment 
of Cancer Therapy Kidney Symptom Index (FKSI) and the 
FKSI-Disease Related Symptoms (FKSI-DRS) subscale, 
which specifically measures symptoms associated with 
advanced RCC.
The AXIS study demonstrated significantly longer 
median progression-free survival with axitinib versus 
sorafenib (6.7 versus 4.7 months, respectively, P,0.0001). In 
this study, axitinib was superior to sorafenib for the primary 
endpoint of progression-free survival, with a statistically 
significant 33% (P,0.0001) overall reduction of risk of 
progression or death, with a hazard ratio (HR) of 0.665 (95% 
CI 0.544–0.812; one-sided P,0.0001). Significant improve-
ments in progression-free survival were also observed in 
patients treated with sunitinib-based or cytokine-based 
therapy (Figure 4).
In the AXIS trial, median progression-free survival 
favored axitinib in patients who had received prior cytok-
ines (12.1 versus 6.5 months; P,0.0001) and those who 
had received prior sunitinib therapy (4.8 versus 3.4 months; 
P=0.0107). In the axitinib arm, axitinib was also observed to 
perform better for the secondary endpoint of overall response 
rate. According to the blinded independent review commit-
tee, subjects in the axitinib treatment arm had an overall 
response rate of 19.4% (95% CI 15.4–23.9), compared with 
9.4% (95% CI 6.6–12.9) for those in the sorafenib treatment 
arm (P=0.0001).
This is the first randomized Phase III study using an 
active comparator (sorafenib), which is a VEGF receptor TKI 
approved for treatment of advanced RCC. The overall survival 
data were published with a cutoff date of November 1, 2011. 
The median overall survival was 20.1 months (95% CI 16.7–
23.4) with axitinib and 19.2 months (17.5–22.3) with sorafenib 
(HR 0.969, 95% CI 0.800–1.174; one-sided P=0.3744).44 
Updated progression-free survival as assessed by the inves-
tigators was also reported. These results are consistent with 
the investigator-assessed median progression-free survivals 
previously reported in the initial AXIS publication.28 Updated 
investigator-assessed median progression-free survival 
was 8.3 months (95% CI 6.7–9.2) with axitinib and 5.7 
months (95% CI 4.7–6.5) with sorafenib (HR 0.656, 95% 
CI 0.552–0.79; one-sided P,0.0001). Updated investigator-
assessed median progression-free survival post-sunitinib was 
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Figure 4 Kaplan–Meier estimated median progression-free survival in patients who 
received axitinib or sorafenib as second-line therapy for metastatic renal cell cancer. 
(A) All patients, (B) patients previously treated with cytokine-based regimen, and 
(C) patients previously treated with sunitinib-based regimen (full analysis set, by 
independent review committee assessment).
Note: P-values based on one-sided, stratified log-rank test. Reprinted from The 
Lancet, vol 378, Rini Bi, escudier B, Tomczak P, et al, Comparative effectiveness 
of axitinib versus sorafenib in advanced renal cell carcinoma (AXiS): a randomised 
phase 3 trial, Pages 1931–1939,28 Copyright © 2011, with permission from elsevier.
Abbreviations: HR, hazard ratio; PFS, progression-free survival; CI, confidence 
interval.
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6.5 months (95% CI 5.7–7.9) with axitinib and 4.4 months 
(2.9–4.7) with sorafenib (HR 0.719, 95% CI 0.572–0.903; 
one-sided P=0.0022). The lack of a statistically significant 
difference in terms of overall survival between axitinib and 
sorafenib in post-sunitinib patients may have been extensively 
debated. However, even if overall survival, which was a sec-
ondary endpoint for the study, did not differ between the two 
arms, it is noteworthy that investigator-assessed progression-
free survival in the axitinib group was significantly longer 
compared with the sorafenib group. The analysis of overall 
survival might have been confounded by subsequent active 
treatments which were given to the majority of patients 
who discontinued study treatment. Furthermore, showing a 
survival advantage is particularly challenging when survival 
post progression is long (.12 months), as seen in the AXIS 
study. Due to the fact that progression-free survival was 
chosen as the primary endpoint of this study and that active 
treatments were available beyond progression, the variability 
introduced by a long survival post progression might have 
diluted the ability to detect a statistically significant differ-
ence in overall survival.45 However, it is not possible to rule 
out that sorafenib may be at least as effective as axitinib in 
prolonging overall survival.
Additional data for axitinib in first-line therapy are 
available from AGILE 1046, a Phase II study in which the 
primary objective was to compare the overall response rate in 
patients randomized to axitinib + active (axitinib) titration 
versus axitinib + placebo titration. The overall response 
rate was 54% versus 34%, respectively (P=0.019) with a 
median  progression-free survival of 14.6 months.46 AGILE 
1051, a Phase III study comparing axitinib with sorafenib, 
failed to meet its ambitious primary endpoint of increas-
ing progression-free survival by 78% in patients treated 
with axitinib. This study found no significant difference in 
median progression-free survival between patients treated 
with axitinib or sorafenib (10.1 months [95% CI 7.2–12.1] 
versus 6.5 months [4.7–8.3], respectively). Although axi-
tinib did not significantly increase progression-free survival 
in first-line treatment of metastatic RCC compared with 
sorafenib, it did demonstrate clinical activity and had a valid 
safety profile47 (Table 3). However, this study halted the 
development of axitinib as first-line therapy for RCC.
At present, AXIS is the only head-to-head randomized 
clinical trial of axitinib versus sorafenib in patients with 
metastatic RCC after a first-line therapy, and supports axi-
tinib as second-line therapy for metastatic RCC after failure 
of prior treatment with sunitinib or a cytokine. Studies 
conducted with targeted therapies in the second-line setting 
have indicated better progression-free survival compared 
with IFN-α and placebo.
TARGET (the Treatment Approaches in Renal Cancer 
Global Evaluation Trial) compared sorafenib versus placebo 
in patients pretreated with a cytokine and demonstrated a 
benefit in terms of progression-free survival in this setting in 
favor of sorafenib.21 Also, the RECORD 1 (Renal Cell cancer 
treatment with Oral RAD001 given Daily) study compared 
everolimus and placebo in patients with metastatic RCC 
which had progressed on VEGF receptor-targeted TKIs. This 
treatment was not only in the second-line setting, but also 
in subsequent lines of therapy since 71% of patients in the 
everolimus group and 79% in the placebo group had pro-
gressed after more than one previous treatment. Everolimus 
significantly prolonged progression-free survival compared 
with placebo (4.9 versus 1.9 months; P#0.001).13 A pivotal 
study also evaluated pazopanib in treatment-naïve patients 
pretreated with a cytokine.24 Based on these studies, sorafenib 
and pazopanib are recommended as second-line therapy 
for patients with metastatic RCC following prior cytokine 
Table 3 Treatment-related adverse events in AGiLe 1046
Axitinib (n=189) Sorafenib (n=96)
All grades, n (%) Grade 3 Grade 4 All grades Grade 3 Grade 4
Diarrhea 94 (50) 17 (9) 0 38 (40) 5 (5) 0
Hypertension 92 (49) 25 (13) 1 28 (29) 1 (1) 0
weight decrease 69 (37) 16 (8) 0 23 (24) 3 (3) 0
Fatigue 62 (37) 9 (5) 1 25 (26) 1 (1) 0
Decreased appetite 54 (29) 4 (2) 0 18 (19) 0 0
PPe 50 (26) 14 (7) 0 37 (39) 15 (16) 0
Dysphonia 44 (23) 2 (1) 0 10 (10) 0 0
Asthenia 39 (21) 13 (7) 3 15 (16) 5 (5) 0
Hypothyroidism 39 (21) 0 0 7 (7) 0 0
Nausea 37 (20) 2 (1) 0 14 (15) 1 (1) 0
Rash 18 (10) 2 (1) 0 19 (20) 1 (1) 0
Abbreviation: PPe, palmar-plantar erythrodysesthesia.
Pharmacogenomics and Personalized Medicine 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
114
verzoni et al
therapy because of the robust Phase III evidence for improved 
progression-free survival with sorafenib and pazopanib 
compared with placebo in this patient group.
Everolimus is recommended as second-line treatment in 
patients with VEGF receptor TKI-refractory metastatic RCC 
because of the significantly improved progression-free sur-
vival found in patients refractory to VEGF-targeted therapy 
(sunitinib and/or sorafenib). The results of the INTORSECT 
(Investigating Torisel As Second-Line Therapy) study com-
paring temsirolimus with sorafenib in patients who progressed 
on treatment with sunitinib at first-line revealed no benefit in 
progression-free survival for temsirolimus arm.48 The TIVO-1 
(Tivozanib Versus Sorafenib in first line Advanced RCC) 
study demonstrated a better progression-free survival of 
11.9 months versus 9.1 months for tivozanib versus sorafenib, 
respectively, in the overall population. In the subgroup of 
treatment-naïve patients (70% of the overall population) the 
progression-free survival was 12.7 months versus 9.1 months 
for tivozanib and sorafenib, respectively.49
Safety and tolerability
The safety profile of axitinib is generally manageable with 
standard medical intervention.50 No unexpected adverse events 
occurred in the Phase II studies. The most common grade 3 
adverse events were hand-foot syndrome, fatigue, hyperten-
sion, and diarrhea. In the Phase III trial, some of the grade 3 
or higher treatment-related adverse events most frequently 
reported with axitinib included hypertension (16%), diar-
rhea (11%), fatigue (11%), and hand-foot syndrome (16%), 
hypertension (11%), and diarrhea (7%) in the sorafenib arm. 
Discontinuation rates due to treatment-related adverse events 
were 4% in the axitinib arm and 8% in the sorafenib arm.28
Proactive assessment and management of these adverse 
events during axitinib therapy can minimize treatment inter-
ruptions and ensure optimal benefit from treatment.51,52 
Recommendations for monitoring, preventing, and treating 
adverse events can reduce the severity and duration of side 
effects, as well as improve dose delivery, which may maximize 
clinical outcomes. Strategies include educating patients about 
potential adverse events, regular monitoring, and concomitant 
treatment of adverse events. With these recommendations, 
the majority of adverse events associated with axitinib can be 
managed while maintaining patients on therapy. Management 
of some adverse reactions may require temporary or perma-
nent discontinuation and/or reduction of the axitinib dose. 
When dose reduction is necessary, according to the pivotal 
Phase III study, the axitinib dose may be reduced to 3 mg twice 
daily and further to 2 mg twice daily. Patients who tolerate 
the axitinib starting dose of 5 mg twice daily with no adverse 
reactions higher than grade 2 (ie, without severe adverse reac-
tions according to Common Terminology Criteria for Adverse 
Events version 3.0) for 2 consecutive weeks may have their 
dose increased to 7 mg twice daily unless blood pressure is 
.150/90 mmHg or the patient is receiving antihypertensive 
treatment. Subsequently, using the same criteria, patients who 
tolerate an axitinib dose of 7 mg twice daily may have their 
dose increased to a maximum of 10 mg twice daily.
Overall, these results demonstrate that axitinib has clini-
cally meaningful efficacy in subjects with advanced RCC. 
Efficacy endpoints, including progression-free survival and 
overall response rate, favored the axitinib treatment arm. The 
adverse events reported for axitinib were generally manage-
able by dosing interruption, dose reduction, and/or standard 
medical therapy.
Patient-reported outcomes
The AXIS trial also included an evaluation of patient-reported 
kidney cancer-specific symptoms/functioning and health sta-
tus as a secondary endpoint. The pivotal AXIS trial evaluated 
the composite endpoint of time to deterioration (defined as 
decrease in quality of life), disease progression, and death. 
More than 90% of questionnaires were completed during 
treatment and able to be analyzed for symptom deterioration. 
The time to deterioration (TTD), assessed by Functional 
Assessment of Cancer Therapy (FACT)-Kidney Symptom 
Index-15 (FKSI-15), reported a 17% risk reduction with 
axitinib versus sorafenib (P=0.014) and a 16% risk reduction 
with axitinib (P=0.0203) for TTD evaluated by FKSI-Disease 
Related Symptoms (FKSI-DRS).28 More detailed analysis of 
secondary endpoints concerning patient-reported outcomes 
data (kidney cancer-specific symptoms, health status) was 
done using the Functional Assessment of Cancer Therapy, 
FKSI, and European Quality of Life questionnaire, 5 dimen-
sions (EQ-5D). The FKSI-15 and EuroQoL (EQ-5D) were 
completed at screening, after every 4 weeks of therapy, at the 
end of the study treatment, and at follow-up (28 days after 
end of therapy). End of treatment and follow-up data were 
collected in different cycles, reflecting the different times that 
patients went off treatment.53 The patient-reported outcomes 
were comparable for second-line axitinib and sorafenib, and 
were maintained at relatively high levels while on treatment, 
albeit worsened at end of treatment. Because the duration 
of treatment was longer with axitinib than with sorafenib, 
time to worsening of symptoms can be delayed longer with 
axitinib. Given that disease-related symptoms and health-
related quality of life are better when patients are on  treatment 
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and progression-free, and axitinib induces significantly lon-
ger progression-free survival compared with sorafenib, the 
patients who receive axitinib are more likely to have longer 
symptom control that is not compensated by a worsening of 
patient-reported outcomes. These results also support the 
treatment with axitinib to delay the worsening of quality of 
life occurring at the discontinuation of therapy.54
Conclusion
The availability of targeted therapies for the treatment of 
advanced metastatic RCC has changed the progression-
free survival and overall survival of these patients. To date, 
seven targeted therapies (sorafenib, sunitinib, bevacizumab/ 
IFN-α combination, temsirolimus, everolimus, pazopanib, 
and axitinib) have been investigated and approved by the US 
Food and Drug Administration and the European Medicines 
Agency. As second-line treatment, after a first-line cytokine-
based therapy, the guidelines of the European Society of 
Medical Oncology (ESMO) recommend sorafenib [I, A], 
pazopanib [II, A], and recently axitinib [I, A]. Sunitinib has 
also demonstrated activity is this setting [III, A]. Based on 
this premise, VEGF-targeted therapy represents the first-line 
standard of care for these patients, and the European Society 
of Medical Oncology guidelines recommend axitinib [I, A] 
and everolimus [II, A].55
Based on the AXIS results demonstrating significantly 
longer median progression-free survival with axitinib versus 
sorafenib (even if no statistically significant differences in 
overall survival were observed) and on the AGILE results 
(where no significant difference in median progression-free 
survival was observed between patients treated with axitinib 
or sorafenib), axitinib was established as a second-line treat-
ment option for patients with metastatic RCC. In the future, 
it will be interesting to explore the use of axitinib further 
in the first-line setting, as well as its role as an adjuvant or 
neoadjuvant therapy. Predictive factors for efficacy of this 
molecule should be identified as well.
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